Search results for " lipid"

showing 10 items of 481 documents

CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells

2004

We investigated the membrane localization of CD95 in type I and type II cells, which differ in their ability to recruit and activate caspase-8. We found that CD95 was preferentially located in lipid rafts of type I cells, while it was present both in raft and non-raft plasma membrane sub-domains of type II cells. After stimulation, CD95 located in phospholipid-rich plasma membrane was recruited to lipid rafts in both types of cells. Similarly, CD95 cross-linking resulted in caspase-independent translocation of FADD/MORT1 and caspase-8 to the lipid rafts, which was prevented by a death domain-defective receptor. CD95 internalization was then rapid in type I and delayed in type II cells and s…

Death Domain Receptor Signaling Adaptor ProteinsEndosomeT-Lymphocytesmedia_common.quotation_subjectImmunologyApoptosisReceptors Tumor Necrosis FactorCell LineMembrane MicrodomainsSettore MED/04 - PATOLOGIA GENERALECell Line TumorReceptorsHumansImmunology and Allergyfas ReceptorFADDInternalizationLipid raftLipid raftsDeath domainmedia_commonTumorbiologyVesicleFas receptorEndocytosisCell biologyProtein TransportCholesterolCD95 death-inducing signaling complexCaspasesCD95biology.proteinlipids (amino acids peptides and proteins)biological phenomena cell phenomena and immunityCaspase-8Tumor Necrosis FactorCaspase-8; CD95; Lipid rafts; Apoptosis; Caspases; Cell Line Tumor; Cholesterol; Death Domain Receptor Signaling Adaptor Proteins; Humans; Membrane Microdomains; Protein Binding; Protein Transport; Receptors Tumor Necrosis Factor; T-Lymphocytes; fas Receptor; Endocytosis; Signal Transduction; Immunology and Allergy; ImmunologyProtein BindingSignal TransductionEuropean Journal of Immunology
researchProduct

Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022)

2022

AbstractDyslipidemia in patients with type 2 diabetes (DMT2) is one of the worst controlled worldwide, with only about 1/4 of patients being on the low-density lipoprotein cholesterol (LDL-C) target. There are many reasons of this, including physicians’ inertia, including diabetologists and cardiologists, therapy nonadherence, but also underusage and underdosing of lipid lowering drugs due to unsuitable cardiovascular (CV) risk stratification. In the last several years there is a big debate on the risk stratification of DMT2 patients, with the strong indications that all patients with diabetes should be at least at high cardiovascular disease (CVD) risk. Moreover, we have finally lipid lowe…

Diabetes Mellitus Type 2 / diagnosisDyslipidemias / drug therapyEndocrinology Diabetes and Metabolism610 Medicine & health2705 Cardiology and Cardiovascular MedicineCardiovascular risk Diabetes Individual therapy approach Lipid lowering therapy StatinsHumansIndividual therapy approachDyslipidemiasHypolipidemic AgentsDiabetes Mellitus Type 2 / epidemiologyDiabetesStatinsCholesterol LDLCardiovascular riskAtherosclerosisDyslipidemias / diagnosis2712 Endocrinology Diabetes and MetabolismDiabetes Mellitus Type 22724 Internal MedicineDyslipidemias / epidemiology10209 Clinic for CardiologyProprotein Convertase 9Diabetes Mellitus Type 2 / drug therapyCardiology and Cardiovascular MedicineLipid lowering therapy
researchProduct

Associations of nutrition and body composition with cardiovascular disease risk factors in soldiers during a 6-month deployment

2020

Objectives This observational follow-up study investigated the associations of nutrition and body composition with cardiovascular disease (CVD) risk factors, including pro-inflammatory biomarkers, in soldiers during a 6-month deployment. Material and Methods Thirty-five male soldiers were assessed at months 0, 3 and 6, and their parameters, i.e., M±SD, were as follows: age 30.0±8.7 years, height 179±6 cm, and BMI 24.2±2.5 kg/m 2 . Three-day food diaries were used for monitoring macronutrient intake. Body composition was estimated using bioimpedance. Fasting blood samples for lipids and pro-inflammatory biomarkers were collected, and blood pressure measurements were performed. Results Carboh…

Dietary FiberMaleSYMPTOMSkolesteroliPhysical fitness0211 other engineering and technologieslcsh:MedicinePROTEINBlood lipidsPhysiologyBLOOD-PRESSURE02 engineering and technologyruokavaliotBody fat percentagesoldierchemistry.chemical_compoundFiber intakeRisk FactorsMedicinesotilaatLebanonFinland05 social sciencesblood pressureGeneral MedicinerauhanturvaoperaatiotDiet Records3142 Public health care science environmental and occupational health0506 political sciencebody fatMilitary PersonnelAdipose TissueCardiovascular DiseasesLow-density lipoproteinBody CompositionSERUM-LIPIDSComposition (visual arts)3143 NutritionAdultPHYSICAL-FITNESS050601 international relationsINFLAMMATIONterveysvaikutuksetHumanscrisis managementkehonkoostumus021110 strategic defence & security studiesCholesterolbusiness.industryterveydentilalcsh:RPublic Health Environmental and Occupational HealthcholesterolCholesterol LDLfiber intakeDietverenpaineBlood pressurechemistryFATravintokuitubusinessInternational Journal of Occupational Medicine and Environmental Health
researchProduct

A small HSP, Lo18, interacts with the cell membrane and modulates lipid physical state under heat shock conditions in a lactic acid bacterium

2005

International audience; The small heat shock proteins (sHSP) are characterized by a chaperone activity to prevent irreversible protein denaturation. This study deals with the sHSP Lo18 induced by multiple stresses in Oenococcus oeni, a lactic acid bacterium. Using in situ immunocytochemistry and cellular fractionation experiments, we demonstrated the association of Lo18 with the membrane in O. oeni cells submitted to heat shock. The same result was obtained after exposure of cells to ethanol or benzyl alcohol, agents known to have an influence on membranes. For the different stresses, the protein was located on the periphery of the cell at membrane level and was also found within the cytopl…

DiphenylhexatrieneHot TemperatureBiophysicsFluorescence PolarizationBiologyBiochemistryImmunolocalizationSmall HSPCell membraneMembrane Lipids03 medical and health scienceschemistry.chemical_compoundHeat shock proteinMembrane fluiditymedicineMembrane fluidityLipid bilayer030304 developmental biologyOenococcus oeni0303 health sciences030306 microbiologyCell MembraneLipid–protein interactionCell Biologybiology.organism_classificationHeat-Shock Proteins SmallGram-Positive CocciMembranemedicine.anatomical_structure[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologychemistryBiochemistryBiophysicsLipochaperoneLaurdanOenococcus oeni
researchProduct

Dietary methods and biomarkers of omega 3 fatty acids: a systematic review

2012

The aims of the present study were to review the validity of dietary methods used to measure the usual long chain (LC) omega-3 polyunsaturated fatty acid (n-3 PUFA) intake of a population and to assess the usefulness of different biomarkers ofn-3 PUFA in healthy humans. Two systematic literature searches were conducted until May 2011 to update previous systematic reviews. The first literature search aimed to find studies validating the methodology used for measuring the dietary intake ofn-3 PUFA. The second search aimed to find human intervention studies in whichn-3 PUFA status changed after 2 weeks ofn-3 PUFA supplementation. Sixteen studies were identified for inclusion in the first revie…

Docosahexaenoic AcidsPopulationSubcutaneous FatNutritional StatusMedicine (miscellaneous)PhysiologyBlood lipidsValidation Studies as TopicSubcutaneous fatReference ValuesFatty Acids Omega-3HumansMedicineFood scienceeducationchemistry.chemical_classificationeducation.field_of_studyNutrition and Dieteticsbusiness.industryDietary intakeDietary FatsLipidsEicosapentaenoic acidDietNutrition AssessmentSystematic reviewchemistryDocosahexaenoic acidDietary Supplementslipids (amino acids peptides and proteins)businessBiomarkersPolyunsaturated fatty acidBritish Journal of Nutrition
researchProduct

Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells

2014

Background: In hepatocellular carcinoma (HCC), different signaling pathways are de-regulated, and among them, the expression of the epidermal growth factor receptor (EGFR). Tyrphostin AG-1478 is a lipophilic low molecular weight inhibitor of EGFR, preferentially acting on liver tumor cells. In order to overcome its poor drug solubility and thus improving its anticancer activity, it was entrapped into nanostructured lipid carriers (NLC) by using safe ingredients for parenteral delivery. Results: Nanostructured lipid carriers (NLC) carrying tyrphostin AG-1478 were prepared by using the nanoprecipitation method and different matrix compositions. The best system in terms of mean size, PDI, zeta…

DrugCarcinoma HepatocellularHepatocellular carcinomamedia_common.quotation_subjectBiomedical EngineeringMedicine (miscellaneous)Pharmaceutical ScienceAntineoplastic AgentsBioengineeringPharmacologyApplied Microbiology and BiotechnologyCell Line TumormedicineHumansEpidermal growth factor receptorNanostructured lipid carriers Tyrphostin AG-1478 Drug release Hepatocellular carcinoma EGFR inhibitor.media_commonEGFR inhibitorsDrug CarriersNanostructured lipid carriersbiologyChemistryResearchLiver NeoplasmsCorrectionDrug releaseTyrphostinsmedicine.diseaseLipidsTyrphostin AG-1478Molecular medicineIn vitroNanostructuresErbB ReceptorsEGFR inhibitorLiverSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoHepatocellular carcinomaDrug deliveryQuinazolinesbiology.proteinMolecular MedicineDrug carrier
researchProduct

Lipid Nanoparticles for Drug Targeting to the Brain

2012

In this chapter, the main production methods of lipid nanostructures such as solid lipid nanoparticles and nanostructured lipid carriers, and their application are described. In particular, we describe the strategies commonly used to obtain lipid nanoparticles to overcome the blood-brain barrier (BBB) for the treatment of several brain diseases. The use of these carriers as targeted drug delivery systems is associated with many advantages that include excellent storage stability, easy production without the use of any organic solvent, the possibility of steam sterilization and lyophilization, and large scale production. They exhibit good stability during long-term storage, consist of physio…

DrugChemistrymedia_common.quotation_subjectOrganic solventNanoparticleNanotechnologySteam sterilizationTargeted drug deliverySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoNanoparticles for drug delivery to the brainGenerally recognized as safeSolid lipid nanoparticlesolid lipid nanoparticles blood brain barriermedia_common
researchProduct

Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug.

2007

An increasing number of newly developed drugs show bioavailability problems due to poor water solubility. Formulating the drugs as nanosuspensions may help to overcome these problems by increasing saturation solubility and dissolution velocity. In the present study the bioavailability of the poorly soluble fenofibrate following oral administration was investigated in rats. Four formulations were tested: a nanosuspension type DissoCube(R), one solid lipid nanoparticle (SLN) preparation and two suspensions of micronized fenofibrate as reference formulations, one suspension in sirupus simplex and a second in a solution of hydroxyethy-cellulose in physiological saline. Both colloidal drug deliv…

DrugMalemedia_common.quotation_subjectPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyModels BiologicalDosage formPharmacokineticsFenofibrateSuspensionsSolid lipid nanoparticlemedicineAnimalsComputer SimulationTissue DistributionSolubilityRats Wistarmedia_commonHypolipidemic AgentsFenofibrateChemistryLipidsBioavailabilityRatsSolubilityDrug deliveryNanoparticlesmedicine.drugAdvanced drug delivery reviews
researchProduct

Hypolipidaemic effects of fenofibrate are not altered by mildronate-mediated normalization of carnitine concentration in rat liver.

1999

The five-fold higher carnitine content in the liver of fenofibrate-treated rats addresses the question about the possible role of this enhancement in the hypolipidaemic effect of the drug and the underlying mechanisms. When fenofibrate was administered with mildronate (a gamma-butyrobetaine hydroxylase inhibitor) in suitable amount, the content in carnitine was found to be normalized in liver. However, triglyceride contents of liver and serum were then at least as low as in rats treated by fenofibrate only. When carnitine concentration was lowered by mildronate to the third of the normal value, a marked increase in triglycerides occurred both in liver and serum, while the five-fold increase…

DrugMalemedicine.medical_specialtymedia_common.quotation_subjectBlood lipidsKetone BodiesBiochemistrychemistry.chemical_compoundFenofibrateInternal medicineCarnitinemedicineAnimalsCarnitineRats WistarMuscle SkeletalBeta oxidationPhospholipidsTriglyceridesmedia_commonHypolipidemic AgentsFenofibrateTriglycerideChemistryMyocardiumGeneral MedicinePeroxisomeRatsEndocrinologyCholesterolBiochemistryLiverKetone bodiesmedicine.drugMethylhydrazinesBiochimie
researchProduct

Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies

2009

The prospect of improved cancer therapy using Solid Lipid Nanoparticles (SLNs) as drug delivery system is promising. Sev- eral obstacles frequently encountered with anticancer compounds, such as poor drug solubility, are overcome by delivering them using SLN. Moreover, the intravenous administration of drugs into SLNs can potentially enhance drug blood circulation time and improve drug per- formance by inducing accumulation into tumours by enhanced permeability and retention (EPR) effect. This paper deals with the devel- opment of SLN containing nimesulide, a non-steroidal anti-inflammatory drug with antitumour effect and low solubility in water. Here, SLNs carrying nimesulide were prepared…

DrugMaterials sciencemedia_common.quotation_subjectsolid lipid nanoparticles nimesulide drug deliveryBiomedical EngineeringPharmaceutical ScienceMedicine (miscellaneous)BioengineeringPharmacologyIn vitroSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoSolid lipid nanoparticleDrug deliveryZeta potentialmedicineSolubilityCytotoxicityBiotechnologymedia_commonNimesulidemedicine.drugCurrent Nanoscience
researchProduct